EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

摘要: Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already become clinically accepted several countries in- outside Europe. PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) currently undergoing clinical validation. Retrospective observational data have documented favourable safety striking responses. Recent results from a prospective trial (phase II) been published confirming high response rates, low toxicity reduction of pain metastatic castration-resistant cancer (mCRPC) patients who had progressed after conventional treatments. Such typically survive for periods less than 1.5 years. This led some facilities to adopt compassionate or unproven use this therapy, even the absence validation within randomised-controlled trial. As result, consistent body evidence exists support efficacy treatment. The purpose guideline assist nuclear medicine specialists deliver PSMA-RLT as an “unproven intervention practice”, accordance best available knowledge.